京新药业：地达西尼的销售工作在正常进行中

Core Viewpoint - The sales efforts for Didasanib by Jingxin Pharmaceutical are proceeding normally, with a focus on enhancing patient accessibility and providing new treatment solutions through hospital admissions and academic promotion activities [1] Company Summary - Jingxin Pharmaceutical (002020) is actively engaged in the sales of Didasanib, indicating a commitment to improving patient access to this treatment option [1]